Cedara Software (Mississauga, Ontario) has agreed to supply Instrumentarium Imaging (Helsinki, Finland) with a customized version of its Cedara I-Acquire/MG digital acquisition software. The software will be used in Instrumentarium's Diamond full-field
Cedara Software (Mississauga, Ontario) has agreed to supply Instrumentarium Imaging (Helsinki, Finland) with a customized version of its Cedara I-Acquire/MG digital acquisition software. The software will be used in Instrumentarium's Diamond full-field digital mammography system. According to the Dec. 19 announcement, I-Acquire will integrate the flat-panel digital detector, controller, and x-ray generator. I-Acquire will also provide automated workflow, image display manipulation, DICOM communication, and information system integration. Its open architecture will allow the future integration of clinical applications and advanced image processing algorithms, according to Cedara.
The company's I-Acquire software will be integrated into a digital radiography product being manufactured in China. I-Acquire will be supplied to Beijing WanDong Medical Equipment, one of China's largest x-ray equipment manufacturers, as part of a deal announced Dec. 13. The transaction with WanDong also includes Cedara's I-SoftView diagnostic workstation. Cedara designed the software to interface with multiple x-ray acquisition devices, including digital flat-panel detectors as well as computed radiography scanners and readers. I-Acquire features multiple control support, patient demographics, procedure input, intuitive image manipulation tools, and image enhancement algorithms that automatically optimize clinical images, quickening patient throughput.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.